Medical affairs, clinical/R&D, and commercial life science teams are likely to continue conducting virtual or hybrid events as travel resumes.
A significant majority of survey respondents in the life science industry believe teams are likely to continue conducting virtual or hybrid engagements as travel resumes in the wake of increasing vaccination rates. Specifically, 72% for medical affairs, 72% for clinical/R&D, and 69% for commercial teams.
The survey was conducted by CBI and Informa Engage for Within3 from February 22 through March 5, 2021. A variety of organizations are represented in the sample, including commercialized small to midsize pharmaceutical companies (35%), large pharmaceutical companies (17%), pre-commercial life science companies (15%), and medical device manufacturers (8%). Other respondents included those within academia, biotech, CMO, CRO, digital health, and health technology.
Virtually all respondent firms operate in the United States (98%), and approximately half operate in the European Union (50%) and the United Kingdom (45%).
“As teams adjusted to the absence of in-person opportunities for their medical affairs, clinical R&D, and commercial teams, robust end-to-end communication platforms like Within3 stepped in to meet their needs,” says Peter Gannon, Senior Vice President of Business Partnerships. Given the ability to increase time at home or in the clinic, and a reduced travel burden for KOLs in particular, these survey data validate what our clients and partners cite as the primary benefits of the Within3 platform.
While it may be extreme to predict the end of one-off, in-person advisory board meetings, virtual engagements and the tools that support them will continue to be mission-critical elements in end-to-end product development and commercial programs for pharmaceutical and medical device teams for the foreseeable future.
Within3 customers report reducing project timelines for care guidance publication and regulatory responses by up to several months and 2-4X gains in the volume of KOL insights as compared to traditional face-to-face engagements. These results help validate the triple-digit growth of life science and medtech communications and development programs run on our platform since 2019. As a result, 20 of the top 20 global pharmaceutical companies run critical engagement programs on Within3.